Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds

Journal of Nutritional Biochemistry

Volumn 22, Issue 9, 2011, Pages 799-806

  Li, Yanyan ^a,b   Wicha, Max S ^c   Schwartz, Steven J ^b   Sun, Duxin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Cancer stem cells; Chemoprevention; Natural dietary compounds

Indexed keywords

BETA CATENIN; COLECALCIFEROL; CURCUMIN; EPIGALLOCATECHIN GALLATE; ISOFLAVONE; LYCOPENE; NATURAL PRODUCT; NOTCH RECEPTOR; PIPERINE; RESVERATROL; SONIC HEDGEHOG PROTEIN; SULFORAPHANE; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL RENEWAL; CHEMOPROPHYLAXIS; FOOD COMPOSITION; HUMAN; NONHUMAN; PANCREAS TUMOR; REVIEW;

ALKALOIDS; ANIMALS; ANTICARCINOGENIC AGENTS; BENZODIOXOLES; BETA CATENIN; CAROTENOIDS; CATECHIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLECALCIFEROL; CURCUMIN; DIET; HUMANS; ISOFLAVONES; NEOPLASMS; NEOPLASTIC STEM CELLS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; SIGNAL TRANSDUCTION; STILBENES; THIOCYANATES; WNT PROTEINS;

ERINACEIDAE;

EID: 79958160079     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.11.001     Document Type: Review

References (189)

1. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg 1963, 105:574-578.
2. Kohn K.W. Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment - fifteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1996, 56:5533-5546.
3. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
4. Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A., Loehrer P.J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987, 316:1435-1440.
5. Stockler M., Wilcken N.R., Ghersi D., Simes R.J. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000, 26:151-168.
6. Lippman M.E. High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. N Engl J Med 2000, 342:1119-1120.
7. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8:806-823.
8. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
9. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
10. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
11. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
12. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
13. Schatton T., Murphy G.F., Frank N.Y., et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
14. Yang Z.F., Ho D.W., Ng M.N., et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
15. Korkaya H., Paulson A., Charafe-Jauffret E., et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, e1000121:7.
16. Shafee N., Smith C.R., Wei S., et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008, 68:3243-3250.
17. Hambardzumyan D., Squatrito M., Holland E.C. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006, 10:454-456.
18. Smith-Warner S.A., Spiegelman D., Yaun S.S., et al. Fruits, vegetables and lung cancer: a pooled analysis of cohort studies. Int J Cancer 2003, 107:1001-1011.
19. Lamartiniere C.A., Cotroneo M.S., Fritz W.A., Wang J., Mentor-Marcel R., Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002, 132:552S-558S.
20. Li Y., Sarkar F.H. Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 2002, 132:3623-3631.
21. Chinni S.R., Li Y., Upadhyay S., Koppolu P.K., Sarkar F.H. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001, 20:2927-2936.
22. Li Y., Li X., Sarkar F.H. Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr 2003, 133:1011-1019.
23. Choudhuri T., Pal S., Agwarwal M.L., Das T., Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002, 512:334-340.
24. Mukhopadhyay A., Bueso-Ramos C., Chatterjee D., Pantazis P., Aggarwal B.B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001, 20:7597-7609.
25. Gupta S., Hussain T., Mukhtar H. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003, 410:177-185.
26. Hastak K., Gupta S., Ahmad N., Agarwal M.K., Agarwal M.L., Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003, 22:4851-4859.
27. Liu S., Dontu G., Wicha M.S. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005, 7:86-95.
28. Sakariassen P.O., Immervoll H., Chekenya M. Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia 2007, 9:882-892.
29. Zhang Y., Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol Sin 2007, 28:1343-1354.
30. Bednar F., Simeone D.M. Pancreatic cancer stem cells and relevance to cancer treatments. J Cell Biochem 2009, 107:40-45.
31. Ischenko I., Seeliger H., Schaffer M., Jauch K.W., Bruns C.J. Cancer stem cells: how can we target them?. Curr Med Chem 2008, 15:3171-3184.
32. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
33. Ginestier C., Hur M.H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
34. Hermann P.C., Huber S.L., Herrler T., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
35. Son M.J., Woolard K., Nam D.H., Lee J., Fine H.A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4:440-452.
36. Dalerba P., Dylla S.J., Park I.K., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007, 104:10158-10163.
37. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
38. Prince M.E., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007, 104:973-978.
39. Bapat S.A., Mali A.M., Koppikar C.B., Kurrey N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005, 65:3025-3029.
40. Fong M.Y., Kakar S.S The role of cancer stem cells and the side population in epithelial ovarian cancer. Histol Histopathol 2010, 25:113-120.
41. Fang D., Nguyen T.K., Leishear K., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65:9328-9337.
42. Li Y., Zhang T., Korkaya H., et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 2010, 16:2580-2590.
43. Kakarala M., Brenner D.E., Korkaya H., et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 2010, 122:777-785.
44. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69:7507-7511.
45. Dontu G., Abdallah W.M., Foley J.M., et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17:1253-1270.
46. Charafe-Jauffret E., Monville F., Ginestier C., Dontu G., Birnbaum D., Wicha M.S. Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008, 75:75-84.
47. Marshall G.P., Reynolds B.A., Laywell E.D. Using the neurosphere assay to quantify neural stem cells in vivo. Curr Pharm Biotechnol 2007, 8:141-145.
48. Hemmati H.D., Nakano I., Lazareff J.A., et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003, 100:15178-15183.
49. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
50. Dick J.E. Breast cancer stem cells revealed. Proc Natl Acad Sci U S A 2003, 100:3547-3549.
51. Liu S., Dontu G., Mantle I.D., et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006, 66:6063-6071.
52. Dontu G., Jackson K.W., McNicholas E., Kawamura M.J., Abdallah W.M., Wicha M.S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004, 6:R605-R615.
53. Smalley M.J., Dale T.C. Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 1999, 18:215-230.
54. Turashvili G., Bouchal J., Burkadze G., Kolar Z. Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 2006, 73:213-223.
55. Polakis P. Wnt signaling and cancer. Genes Dev 2000, 14:1837-1851.
56. Yamaguchi T.P. Heads or tails: Wnts and anterior-posterior patterning. Curr Biol 2001, 11:R713-R724.
57. Akiyama T. Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 2000, 11:273-282.
58. Kawaguchi-Ihara N., Murohashi I., Nara N., Tohda S. Promotion of the self-renewal capacity of human acute leukemia cells by Wnt3A. Anticancer Res 2008, 28:2701-2704.
59. Khan N.I., Bradstock K.F., Bendall L.J. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol 2007, 138:338-348.
60. Ysebaert L., Chicanne G., Demur C., et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006, 20:1211-1216.
61. Chien A.J., Moore E.C., Lonsdorf A.S., et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 2009, 106:1193-1198.
62. Li Y., Welm B., Podsypanina K., et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A 2003, 100:15853-15858.
63. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 2007, 104:618-623.
64. Schulenburg A., Cech P., Herbacek I., et al. CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol 2007, 213:152-160.
65. Yang W., Yan H.X., Chen L., et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008, 68:4287-4295.
66. Teng Y., Wang X., Wang Y., Ma D. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun 2010, 392:373-379.
67. Nelson W.J., Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303:1483-1487.
68. He T.C., Sparks A.B., Rago C., et al. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
69. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
70. Mann B., Gelos M., Siedow A., et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 1999, 96:1603-1608.
71. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
72. Lin S.Y., Xia W., Wang J.C., et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 2000, 97:4262-4266.
73. Orsulic S., Huber O., Aberle H., Arnold S., Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci 1999, 112(Pt 8):1237-1245.
74. Schweizer L., Varmus H. Wnt/Wingless signaling through beta-catenin requires the function of both LRP/Arrow and frizzled classes of receptors. BMC Cell Biol 2003, 4:4.
75. Takahashi-Yanaga F., Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008, 20:581-589.
76. Liu C., Li Y., Semenov M., et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108:837-847.
77. Pap M., Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 1998, 273:19929-19932.
78. Yost C., Torres M., Miller J.R., Huang E., Kimelman D., Moon R.T. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996, 10:1443-1454.
79. Cohen P., Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001, 2:769-776.
80. Cohen M.M. The hedgehog signaling network. Am J Med Genet A 2003, 123A:5-28.
81. Clement V., Sanchez P., de Tribolet N., Radovanovic I., Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007, 17:165-172.
82. Lewis M.T., Veltmaat J.M. Next stop, the twilight zone: hedgehog network regulation of mammary gland development. J Mammary Gland Biol Neoplasia 2004, 9:165-181.
83. Pasca di Magliano M., Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 2003, 3:903-911.
84. Nakashima H., Nakamura M., Yamaguchi H., et al. Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res 2006, 66:7041-7049.
85. Kasperczyk H., Baumann B., Debatin K.M., Fulda S. Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo. FASEB J 2009, 23:21-33.
86. Wang Z., Li Y., Banerjee S., Sarkar F.H. Emerging role of Notch in stem cells and cancer. Cancer Lett 2009, 279:8-12.
87. Wilson A., Radtke F. Multiple functions of Notch signaling in self-renewing organs and cancer. FEBS Lett 2006, 580:2860-2868.
88. Peacock C.D., Watkins D.N. Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 2008, 26:2883-2889.
89. Fan X., Eberhart C.G. Medulloblastoma stem cells. J Clin Oncol 2008, 26:2821-2827.
90. Kakarala M., Wicha M.S. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008, 26:2813-2820.
91. Scoville D.H., Sato T., He X.C., Li L. Current view: intestinal stem cells and signaling. Gastroenterology 2008, 134:849-864.
92. Farnie G., Clarke R.B. Mammary stem cells and breast cancer - role of Notch signalling. Stem Cell Rev 2007, 3:169-175.
93. Mumm J.S., Kopan R. Notch signaling: from the outside in. Dev Biol 2000, 228:151-165.
94. Wu J.Y., Rao Y. Fringe: defining borders by regulating the notch pathway. Curr Opin Neurobiol 1999, 9:537-543.
95. Borggrefe T., Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009, 66:1631-1646.
96. Weng A.P., Millholland J.M., Yashiro-Ohtani Y., et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006, 20:2096-2109.
97. Satoh Y., Matsumura I., Tanaka H., et al. Roles for c-Myc in self-renewal of hematopoietic stem cells. J Biol Chem 2004, 279:24986-24993.
98. Palomero T., Lim W.K., Odom D.T., et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006, 103:18261-18266.
99. Ronchini C., Capobianco A.J. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 2001, 21:5925-5934.
100. Rangarajan A., Talora C., Okuyama R., et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001, 20:3427-3436.
101. Oswald F., Liptay S., Adler G., Schmid R.M. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 1998, 18:2077-2088.
102. Jang M.S., Miao H., Carlesso N., et al. Notch-1 regulates cell death independently of differentiation in murine erythroleukemia cells through multiple apoptosis and cell cycle pathways. J Cell Physiol 2004, 199:418-433.
103. Nickoloff B.J., Qin J.Z., Chaturvedi V., Denning M.F., Bonish B., Miele L. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ 2002, 9:842-855.
104. Wang Y., Chan S.L., Miele L., et al. Involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci U S A 2004, 101:9458-9462.
105. Shin H.M., Minter L.M., Cho O.H., et al. Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J 2006, 25:129-138.
106. Wang J., Shelly L., Miele L., Boykins R., Norcross M.A., Guan E. Human Notch-1 inhibits NF-kappa B activity in the nucleus through a direct interaction involving a novel domain. J Immunol 2001, 167:289-295.
107. Wang Z., Banerjee S., Li Y., Rahman K.M., Zhang Y., Sarkar F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006, 66:2778-2784.
108. Chen Y., Shu W., Chen W., Wu Q., Liu H., Cui G. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin Pharmacol Toxicol 2007, 101:427-433.
109. Cheng P., Zlobin A., Volgina V., et al. Notch-1 regulates NF-kappaB activity in hemopoietic progenitor cells. J Immunol 2001, 167:4458-4467.
110. Kawasaki B.T., Hurt E.M., Mistree T., Farrar W.L. Targeting cancer stem cells with phytochemicals. Mol Interv 2008, 8:174-184.
111. Park C.H., Hahm E.R., Park S., Kim H.K., Yang C.H. The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett 2005, 579:2965-2971.
112. Satoskar R.R., Shah S.J., Shenoy S.G. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 1986, 24:651-654.
113. Shao Z.M., Shen Z.Z., Liu C.H., et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 2002, 98:234-240.
114. Jaiswal A.S., Marlow B.P., Gupta N., Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002, 21:8414-8427.
115. Yan C., Jamaluddin M.S., Aggarwal B., Myers J., Boyd D.D. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther 2005, 4:233-241.
116. Ryu M.J., Cho M., Song J.Y., et al. Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem Biophys Res Commun 2008, 377:1304-1308.
117. Wang Z., Zhang Y., Banerjee S., Li Y., Sarkar F.H. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006, 106:2503-2513.
118. Kakarala M., Brenner D.E., Korkaya H., et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 2010, 122:777-785.
119. Zhang Y., Talalay P., Cho C.G., Posner G.H. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A 1992, 89:2399-2403.
120. Clarke J.D., Dashwood R.H., Ho E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 2008, 269:291-304.
121. Fahey J.W., Zhang Y., Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci U S A 1997, 94:10367-10372.
122. Fahey J.W., Haristoy X., Dolan P.M., et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A 2002, 99:7610-7615.
123. Zhang Y., Kensler T.W., Cho C.G., Posner G.H., Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci U S A 1994, 91:3147-3150.
124. Chung F.L., Conaway C.C., Rao C.V., Reddy B.S. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 2000, 21:2287-2291.
125. Singh A.V., Xiao D., Lew K.L., Dhir R., Singh S.V. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 2004, 25:83-90.
126. Jackson S.J., Singletary K.W. Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis 2004, 25:219-227.
127. Kallifatidis G., Rausch V., Baumann B., et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009, 58:949-963.
128. Choi S., Lew K.L., Xiao H., et al. d,l-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. Carcinogenesis 2007, 28:151-162.
129. Xu C., Shen G., Chen C., Gelinas C., Kong A.N. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene 2005, 24:4486-4495.
130. Jeong W.S., Kim I.W., Hu R., Kong A.N. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res 2004, 21:661-670.
131. Khor T.O., Hu R., Shen G., et al. Pharmacogenomics of cancer chemopreventive isothiocyanate compound sulforaphane in the intestinal polyps of ApcMin/+ mice. Biopharm Drug Dispos 2006, 27:407-420.
132. Park S.Y., Kim G.Y., Bae S.J., Yoo Y.H., Choi Y.H. Induction of apoptosis by isothiocyanate sulforaphane in human cervical carcinoma HeLa and hepatocarcinoma HepG2 cells through activation of caspase-3. Oncol Rep 2007, 18:181-187.
133. Shen G., Khor T.O., Hu R., et al. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res 2007, 67:9937-9944.
134. Chaudhuri D., Orsulic S., Ashok B.T. Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. Mol Cancer Ther 2007, 6:334-345.
135. Shankar S., Ganapathy S., Srivastava R.K. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res 2008, 14:6855-6866.
136. Ziegler R.G., Hoover R.N., Pike M.C., et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993, 85:1819-1827.
137. Iwasaki M., Inoue M., Otani T., et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol 2008, 26:1677-1683.
138. Verheus M., van Gils C.H., Keinan-Boker L., Grace P.B., Bingham S.A., Peeters P.H. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol 2007, 25:648-655.
139. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr 1995, 125:777S-783S.
140. Li Y., Wang Z., Kong D., Li R., Sarkar S.H., Sarkar F.H. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J Biol Chem 2008, 283:27707-27716.
141. Sarkar F.H., Li Y., Wang Z., Kong D. Cellular signaling perturbation by natural products. Cell Signal 2009, 21:1541-1547.
142. Su Y., Simmen R.C. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin signaling in mammary epithelial cells. Carcinogenesis 2009, 30:331-339.
143. Su Y., Simmen F.A., Xiao R., Simmen R.C. Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiol Genomics 2007, 30:8-16.
144. Wang Z., Zhang Y., Li Y., Banerjee S., Liao J., Sarkar F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006, 5:483-493.
145. Wang Z., Zhang Y., Banerjee S., Li Y., Sarkar F.H. Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer 2006, 118:1930-1936.
146. Davis J.N., Kucuk O., Sarkar F.H. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 1999, 35:167-174.
147. Chen C.C., Sun Y.T., Chen J.J., Chiu K.T. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway. J Immunol 2000, 165:2719-2728.
148. Natarajan K., Manna S.K., Chaturvedi M.M., Aggarwal B.B. Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65, and subsequent gene expression. Arch Biochem Biophys 1998, 352:59-70.
149. Landis-Piwowar K.R., Huo C., Chen D., et al. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 2007, 67:4303-4310.
150. Fujiki H. Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 1999, 125:589-597.
151. Shimizu M., Deguchi A., Lim J.T., Moriwaki H., Kopelovich L., Weinstein I.B. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005, 11:2735-2746.
152. Kim J., Zhang X., Rieger-Christ K.M., et al. Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J Biol Chem 2006, 281:10865-10875.
153. Bose M., Hao X., Ju J., et al. Inhibition of tumorigenesis in ApcMin/+ mice by a combination of (-)-epigallocatechin-3-gallate and fish oil. J Agric Food Chem 2007, 55:7695-7700.
154. Ju J., Hong J., Zhou J.N., et al. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 2005, 65:10623-10631.
155. Peng G., Dixon D.A., Muga S.J., Smith T.J., Wargovich M.J. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinog 2006, 45:309-319.
156. Li Y., Zhang T., Jiang Y., Lee H.F., Schwartz S.J., Sun D. (-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2. Mol Pharm 2009, 6:1152-1159.
157. Ahmad N., Gupta S., Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 2000, 376:338-346.
158. Afaq F., Adhami V.M., Ahmad N., Mukhtar H. Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea constituent (-)-epigallocatechin-3-gallate. Oncogene 2003, 22:1035-1044.
159. Guo S., Lu J., Subramanian A., Sonenshein G.E. Microarray-assisted pathway analysis identifies mitogen-activated protein kinase signaling as a mediator of resistance to the green tea polyphenol epigallocatechin 3-gallate in her-2/neu-overexpressing breast cancer cells. Cancer Res 2006, 66:5322-5329.
160. Kim S.J., Jeong H.J., Lee K.M., et al. Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem 2007, 18:587-596.
161. Harikumar K.B., Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7:1020-1035.
162. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004, 24:2783-2840.
163. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila Pa) 2009, 2:409-418.
164. Hope C., Planutis K., Planutiene M., et al. Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention. Mol Nutr Food Res 2008, 52(Suppl 1):S52-S61.
165. Roccaro A.M., Leleu X., Sacco A., et al. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenstrom's macroglobulinemia. Clin Cancer Res 2008, 14:1849-1858.
166. Cecchinato V., Chiaramonte R., Nizzardo M., et al. Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol 2007, 74:1568-1574.
167. van Breemen R.B., Pajkovic N. Multitargeted therapy of cancer by lycopene. Cancer Lett 2008, 269:339-351.
168. Nahum A., Zeller L., Danilenko M., et al. Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. Eur J Nutr 2006, 45:275-282.
169. Nahum A., Hirsch K., Danilenko M., et al. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene 2001, 20:3428-3436.
170. Hantz H.L., Young L.F., Martin K.R. Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med (Maywood) 2005, 230:171-179.
171. Salman H., Bergman M., Djaldetti M., Bessler H. Lycopene affects proliferation and apoptosis of four malignant cell lines. Biomed Pharmacother 2007, 61:366-369.
172. Lian F., Smith D.E., Ernst H., Russell R.M., Wang X.D. Apo-19'-lycopenoic acid inhibits lung cancer cell growth in vitro, and suppresses lung tumorigenesis in the A/J mouse model in vivo. Carcinogenesis 2007, 28:1567-1574.
173. Fornelli F., Leone A., Verdesca I., Minervini F., Zacheo G. The influence of lycopene on the proliferation of human breast cell line (MCF-7). Toxicol In Vitro 2007, 21:217-223.
174. Gunasekera R.S., Sewgobind K., Desai S., et al. Lycopene and lutein inhibit proliferation in rat prostate carcinoma cells. Nutr Cancer 2007, 58:171-177.
175. Tang L., Jin T., Zeng X., Wang J.S. Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. J Nutr 2005, 135:287-290.
176. Nagasawa H., Mitamura T., Sakamoto S., Yamamoto K. Effects of lycopene on spontaneous mammary tumour development in SHN virgin mice. Anticancer Res 1995, 15:1173-1178.
177. Sharoni Y., Giron E., Rise M., Levy J. Effects of lycopene-enriched tomato oleoresin on 7,12-dimethyl-benz[a]anthracene-induced rat mammary tumors. Cancer Detect Prev 1997, 21:118-123.
178. Tang F.Y., Shih C.J., Cheng L.H., Ho H.J., Chen H.J. Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway. Mol Nutr Food Res 2008, 52:646-654.
179. Bhardwaj R.K., Glaeser H., Becquemont L., Klotz U., Gupta S.K., Fromm M.F. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002, 302:645-650.
180. Pradeep C.R., Kuttan G. Piperine is a potent inhibitor of nuclear factor-kappaB (NF-kappaB), c-Fos, CREB, ATF-2 and proinflammatory cytokine gene expression in B16F-10 melanoma cells. Int Immunopharmacol 2004, 4:1795-1803.
181. Pradeep C.R., Kuttan G. Effect of piperine on the inhibition of lung metastasis induced B16F-10 melanoma cells in mice. Clin Exp Metastasis 2002, 19:703-708.
182. Selvendiran K., Banu S.M., Sakthisekaran D. Protective effect of piperine on benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Clin Chim Acta 2004, 350:73-78.
183. Selvendiran K., Prince Vijeya Singh J., Sakthisekaran D. In vivo effect of piperine on serum and tissue glycoprotein levels in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. Pulm Pharmacol Ther 2006, 19:107-111.
184. Kumar S., Singhal V., Roshan R., Sharma A., Rembhotkar G.W., Ghosh B. Piperine inhibits TNF-alpha induced adhesion of neutrophils to endothelial monolayer through suppression of NF-kappaB and IkappaB kinase activation. Eur J Pharmacol 2007, 575:177-186.
185. Shin M.H., Holmes M.D., Hankinson S.E., Wu K., Colditz G.A., Willett W.C. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 2002, 94:1301-1311.
186. Grant W.B., Garland C.F. Evidence supporting the role of vitamin D in reducing the risk of cancer. J Intern Med 2002, 252:178-179. [author reply 9-80].
187. Guyton K.Z., Kensler T.W., Posner G.H. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev 2003, 61:227-238.
188. Danilenko M., Studzinski G.P. Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs. Exp Cell Res 2004, 298:339-358.
189. Palmer H.G., Gonzalez-Sancho J.M., Espada J., et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001, 154:369-387.